Challenges and opportunities of pharmacogenetics in drug development

被引：3

作者：

March, Ruth ^{[1
]}

机构：

[1] AstraZeneca, R&D Genet, Macclesfield SK10 4TG, Cheshire, England

来源：

PERSONALIZED MEDICINE | 2006年 / 3卷 / 02期

关键词：

biomarker; drug development; pharmaceutical industry; pharmacogenetics; pharmacogenomics; translational science;

D O I：

10.2217/17410541.3.2.195

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drugs fail the regulatory process for a variety of reasons, including issues with pharmacokinetics, safety and efficacy. One of the most exciting questions in drug development today is how far the science of pharmacogenetics, the study of the genetics of drug response, can be used to address the fundamental issues that the pharmaceutical industry is facing. In particular, the question of how far it is possible to use this emerging science to deliver the right treatment, to the right patient, at the right dose, at the right time is both the challenge and opportunity of using pharmacogenetics in drug development. This review will address these questions with several real-life examples.

引用

页码：195 / 206

页数：12

共 37 条

[1] Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group [J].

Anderson D.C. ;

Gomez-Mancilla B. ;

Spear B.B. ;

Barnes D.M. ;

Cheeseman K. ;

Shaw P.M. ;

Friedman J. ;

McCarthy A. ;

Brazell C. ;

Ray S.C. ;

McHale D. ;

Hashimoto L. ;

Sandbrink R. ;

Watson M.L. ;

Salerno R.A. ;

Cohen N. ;

Lister C.E. .

The Pharmacogenomics Journal, 2002, 2 (5) :284-292

[2] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[3]

BRIDGLANDTAYLOR MH, 2006, J PHARM TOXICOL METH

[4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[5] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[6] Novel technology and the development of pharmacogenetics within the pharmaceutical industry [J].

Gibson, N ;

Jawaid, A ;

March, R .

PHARMACOGENOMICS, 2005, 6 (04) :339-356

[7] The development and clinical use of trastuzumab (Herceptin) [J].

Harries, M ;

Smith, I .

[8] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[9]

HIRSCH F, 2005, AACR NCI EORTC INT C

[10]

HOLLOWAY B, 2005, AACR NCI EORTC INT C

← 1 2 3 4 →